A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Trial details
- Registry ID
- NCT03697109
- Phase
- Phase 3
The FDA approved Relacorilant (CORT125134) on 25 Mar 2026.
Drug identity checked against registry records
Also recorded as CORT125134
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeNCT03697109 | Corcept Therapeutics | Phase 3 | Completed | 2024-04-08Actual |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317 | Corcept Therapeutics | Phase 2 | Recruiting | 2027-09Estimated |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812 | Corcept Therapeutics | Phase 2 | Completed | 2021-03-16Actual |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasNCT04308590 | Corcept Therapeutics | Phase 3 | Completed | 2024-09-19Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-03-25Day | Relacorilant | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220641", "applicant_as_listed_by_fda": "CORCEPT THERAP", "brand_names": ["LIFYORLI (COPACKAGED)"], "active_ingredients": ["RELACORILANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260325", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |